keyword
MENU ▼
Read by QxMD icon Read
search

braf thyroid

keyword
https://www.readbyqxmd.com/read/28805135/intermittent-dosing-of-dabrafenib-and-trametinib-in-metastatic-brafv600e-mutated-papillary-thyroid-cancer-two-case-reports
#1
Paul S White, Anita Pudusseri, Stephanie L Lee, Omar Eton
BACKGROUND: A multi-institutional randomized Phase II trial of continuous dosing of dabrafenib with or without trametinib is ongoing in metastatic thyroid cancer. Preclinical evidence and emerging clinical experience in other cancers support evaluating intermittent dosing of these two agents to achieve more durable response, while being better tolerated and more cost effective. PATIENTS: Two consecutive patients with symptomatic, metastatic radioactive iodine (RAI) resistant BRAF V600E mutated papillary thyroid cancer and poor performance status were treated initially with dabrafenib 150mg twice daily plus trametinib 2mg once daily, first in continuous daily dosing, then in a five-week-on and three-week-off schedule...
August 12, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28791253/potential-role-of-metabolic-intervention-in-the-management-of-advanced-differentiated-thyroid-cancer
#2
Sri Harsha Tella, Anuhya Kommalapati, Mary Angelynne Esquivel, Ricardo Correa
Well-differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy that has an excellent prognosis with a 5-year survival rate of about 98%. However, approximately 50% of the patients with DTC who present with distant metastases (advanced DTC) die from the disease within 5 years of initial diagnosis even after getting the appropriate therapy. Apart from recent advancements in chemotherapy agents, the potential role of metabolic interventions, including the use of metformin, ketogenic diet, and high-dose vitamin C in the management of advanced cancers have been investigated as a less toxic co-adjuvant therapies...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28780248/invasive-follicular-variant-of-papillary-thyroid-cancer-harboring-the-nras-mutation-q61k-and-presenting-with-bone-metastasis-a-case-report
#3
Raman Mehrzad, Michiya Nishino, Carmelo Nucera, Dora Dias-Santagata, James V Hennessey, Per-Olof Hasselgren
INTRODUCTION: The follicular variant of papillary thyroid cancer (FVPTC) can be noninvasive or invasive. The invasive form of FVPTC commonly harbors BRAF mutations whereas RAS mutations are more often associated with noninvasive FVPTC and a favorable clinical outcome. CASE REPORT: A 47-year-old man presented with a metastasis to his right iliac bone as the initial manifestation of a 1.6cm invasive FVPTC. After total thyroidectomy, the patient underwent additional treatment, including thyroid hormone suppressive treatment to non-detectable TSH levels, repeated courses of radioiodine treatment, external beam radiation, and treatment with the tyrosine kinase inhibitor sorafenib...
July 20, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28772138/exposure-to-flame-retardant-chemicals-and-occurrence-and-severity-of-papillary-thyroid-cancer-a-case-control-study
#4
Kate Hoffman, Amelia Lorenzo, Craig M Butt, Stephanie C Hammel, Brittany Bohinc Henderson, Sanziana A Roman, Randall P Scheri, Heather M Stapleton, Julie Ann Sosa
BACKGROUND: Thyroid cancer is the fastest increasing cancer in the U.S., and papillary thyroid cancer (PTC) accounts for >80% of incident cases. Increasing exposure to flame retardant chemicals (FRs) has raised concerns about their possible role in this 'epidemic'. The current study was designed to test the hypothesis that higher exposure to FRs is associated with increased odds of PTC. METHODS: PTC patients at the Duke Cancer Institute were approached and invited to participate...
July 31, 2017: Environment International
https://www.readbyqxmd.com/read/28769567/thyroid-cancer-in-a-patient-with-lynch-syndrome-case-report-and-literature-review
#5
Monika Fazekas-Lavu, Andrew Parker, Allan D Spigelman, Rodney J Scott, Richard J Epstein, Michael Jensen, Katherine Samaras
Lynch syndrome describes a familial cancer syndrome comprising germline mutations in one of four DNA mismatch repair genes, MLH1, MSH2, MSH6, and PMS2 and is characterized by colorectal, endometrial, and other epithelial malignancies. Thyroid cancer is not usually considered to be part of the constellation of Lynch syndrome cancers nor have Lynch syndrome tumor gene mutations been reported in thyroid malignancies. This study reports a woman with Lynch syndrome (colonic cancer and a DNA mismatch repair mutation in the MSH2 gene) with a synchronous papillary thyroid cancer...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28756651/relationship-between-driver-gene-mutations-their-relative-protein-expressions-and-survival-in-non-small-cell-lung-carcinoma-in-macao
#6
Kin Iong Chan, Hong Ting Vong, Lai Fang Sin, Yuk Ching Yip, Xue Yun Zhong, Jian Ming Wen
Objectives We report the status of most common gene mutations in non-small cell lung carcinoma (NSCLC) in Macao, and explore the relationship between each gene mutation and clinicopathologic features and survival. Methods EGFR, KRAS and BRAF mutations were detected by PCR in 122 cases of NSCLC. ALK translocation and MET amplification were detected by fluorescence in situ hybridization (FISH). MET and thyroid transcription factor (TTF-1) were investigated by immunohistochemistry. Clinical data were collected for analyzing their correlation with the gene mutations...
July 29, 2017: Clinical Respiratory Journal
https://www.readbyqxmd.com/read/28750524/nanolock-nanopore-facilitated-digital-diagnostics-of-cancer-driver-mutation-in-tumor-tissue
#7
Yong Wang, Kai Tian, Ruicheng Shi, Amy Gu, Michael Pennella, Lindsey Alberts, Kent S Gates, Guangfu Li, Hongxin Fan, Michael X Wang, Li-Qun Gu
Cancer driver mutations are clinically significant biomarkers. In precision medicine, accurate detection of these oncogenic changes in patients would enable early diagnostics of cancer, individually tailored targeted therapy, and precise monitoring of treatment response. Here we investigated a novel nanolock-nanopore method for single-molecule detection of a serine/threonine protein kinase gene BRAF V600E mutation in tumor tissues of thyroid cancer patients. The method lies in a noncovalent, mutation sequence-specific nanolock...
July 28, 2017: ACS Sensors
https://www.readbyqxmd.com/read/28731042/molecular-alterations-of-coexisting-thyroid-papillary-carcinoma-and-anaplastic-carcinoma-identification-of-tert-mutation-as-an-independent-risk-factor-for-transformation
#8
Naoki Oishi, Tetsuo Kondo, Aya Ebina, Yukiko Sato, Junko Akaishi, Rumi Hino, Noriko Yamamoto, Kunio Mochizuki, Tadao Nakazawa, Hiroshi Yokomichi, Koichi Ito, Yuichi Ishikawa, Ryohei Katoh
Thyroid papillary carcinoma is the most common endocrine neoplasm and generally carries a favorable prognosis. However, a small subset of papillary carcinomas transforms into anaplastic carcinoma, an undifferentiated cancer with a dismal prognosis. Recent studies using next-generation sequencing revealed the genomic landscape of papillary carcinoma and anaplastic carcinoma. However, risk factors for anaplastic transformation in papillary carcinoma remain obscure. In the present study, we investigated molecular alterations of papillary carcinoma and anaplastic carcinoma components in 27 tumors in which anaplastic carcinoma coexisted with antecedent papillary carcinoma...
July 21, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28718951/response-to-therapy-of-papillary-thyroid-cancer-of-known-braf-status
#9
Aldona Kowalska, Agnieszka Walczyk, Artur Kowalik, Iwona Pałyga, Danuta Gąsior-Perczak, Tomasz Trybek, Janusz Kopczyński, Maciej Kajor, Estera Mikina, Monika Szymonek, Klaudia Gadawska-Juszczyk, Dorota Szyska-Skrobot, Katarzyna Lizis-Kolus, Stefan Hurej, Magdalena Chrapek, Małgorzata Chłopek, Stanisław Góźdź
CONTEXT: A dynamic risk stratification with modified initial estimated risk based on response to therapy and disease course is one of the crucial changes adopted recently by the American Thyroid Association (ATA). This approach focuses on an individualized risk-adapted approach to the management of differentiated thyroid cancer. The BRAF V600E mutation is the most common genetic alteration in papillary thyroid cancer (PTC). However, the prognostic value of this mutation remains unclear...
July 18, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/28710706/synchronous-and-metastatic-papillary-and-follicular-thyroid-carcinomas-with-unique-molecular-signatures
#10
Vincent Cracolici, Ibro Mujacic, Sabah Kadri, Mir Alikhan, Nifang Niu, Jeremy P Segal, Lauren E Rosen, David H Sarne, Adam Morgan, Samy Desouky, Nicole A Cipriani
Despite the relatively high prevalence of thyroid cancer, the occurrence of multiple synchronous, distinct subtypes of primary thyroid carcinoma is uncommon. The incidental finding of papillary thyroid microcarcinoma in a gland with a biologically relevant follicular or medullary carcinoma is more frequent than the synchronous occurrence of multiple clinically significant carcinomas. We report a case of synchronous papillary and follicular thyroid carcinomas metastatic to lymph node and bone, respectively. Next generation sequencing showed BRAF V600E mutation in the primary papillary carcinoma and NRAS Q61R mutation in the primary follicular carcinoma and bony metastasis...
July 14, 2017: Endocrine Pathology
https://www.readbyqxmd.com/read/28699904/the-anti-apoptotic-bag3-protein-is-involved-in-braf-inhibitor-resistance-in-melanoma-cells
#11
Luana Guerriero, Giuseppe Palmieri, Margot De Marco, Antonio Cossu, Paolo Remondelli, Mario Capunzo, Maria Caterina Turco, Alessandra Rosati
BAG3 protein, a member of BAG family of co-chaperones, has a pro-survival role in several tumour types. BAG3 anti-apoptotic properties rely on its characteristic to bind several intracellular partners, thereby modulating crucial events such as apoptosis, differentiation, cell motility, and autophagy. In human melanomas, BAG3 positivity is correlated with the aggressiveness of the tumour cells and can sustain IKK-γ levels, allowing a sustained activation of NF-κB. Furthermore, BAG3 is able to modulate BRAFV600E levels and activity in thyroid carcinomas...
June 30, 2017: Oncotarget
https://www.readbyqxmd.com/read/28699414/role-of-ultrasound-in-predicting-tumor-invasiveness-in-follicular-variant-of-papillary-thyroid-carcinoma
#12
Soo Yeon Hahn, Jung Hee Shin, Young Lyun Oh, Tae Hyuk Kim, Yaeji Lim, Ji Soo Choi
BACKGROUND: Follicular variant of papillary thyroid carcinoma (FVPTC) is traditionally divided into infiltrative and encapsulated types. Adding to this classification, noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) represents a reclassification of a subset of cases (encapsulated tumors without lymphovascular or capsular invasion). The purpose of this study was to assess the role of ultrasound (US) in predicting tumor invasiveness in FVPTC. METHODS: From January 2014 to May 2016, preoperative US examinations were performed on 151 patients with 152 FVPTCs who underwent surgery...
August 7, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28687736/association-between-braf-v600e-mutation-and-ultrasound-features-in-papillary-thyroid-carcinoma-patients-with-and-without-hashimoto-s-thyroiditis
#13
Qin Zhang, Bo-Ji Liu, Wei-Wei Ren, Ya-Ping He, Xiao-Long Li, Chong-Ke Zhao, Yi-Feng Zhang, Wen-Wen Yue, Jia-Yi Zheng, Hui-Xiong Xu
To assess the association between BRAF V600E mutation and ultrasound (US) features in papillary thyroid carcinoma (PTC) patients with and without Hashimoto's thyroiditis (HT). We retrospectively reviewed the US features and status of BRAF V600E mutation in 438 consecutive patients with surgically confirmed PTCs. The association between BRAF mutation and US features were analyzed. In addition, we conducted subgroup analyses in terms of coexistent HT. The BRAF mutation was found in 86.5% of patients (379 of 438)...
July 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28687160/prognostic-value-of-putative-cancer-stem-cell-markers-cd24-cd44-cd133-and-aldh1-in-human-papillary-thyroid-carcinoma
#14
Sang-Ah Han, Jae Hoon Jang, Kyu Yeoun Won, Sung-Jig Lim, Jeong-Yoon Song
We hypothesized that cancer stem cells (CSCs) are responsible for the poor outcome and aggressive clinicopathological factors. We surveyed the expression of selected CSC markers that are specifically expressed in thyroid papillary carcinoma (PTC). A total of 80 patients with PTC from 2011 to 2012 were enrolled. We selected CD24, CD44, CD133, and dehydrogenase 1 (ALDH1), as they have been suggested to be candidate CSC markers. Expression of these markers was investigated by immunohistochemical (IHC) staining...
August 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28681580/retrospective-cytological-evaluation-of-indeterminate-thyroid-nodules-according-to-the-british-thyroid-association-2014-classification-and-comparison-of-clinical-evaluation-and-outcomes
#15
Massimo Giusti, Barbara Massa, Margherita Balestra, Paola Calamaro, Stefano Gay, Simone Schiaffino, Giovanni Turtulici, Simonetta Zupo, Eleonora Monti, Gianluca Ansaldo
The cytology of 130 indeterminate nodules (Thy 3) was retrospectively reviewed according to the British Thyroid Association 2014 classification. Nodules were divided into Thy 3a (atypical features) and Thy 3f (follicular lesion) categories. Histology was available as a reference for 97 nodules. Pre-surgical evaluations comprised biochemical tests, color-Doppler ultrasonography (US), semi-quantitative elastography-US (USE), contrast-enhanced US (CEUS), and mutation analysis from cytological slides. Thyroid malignancy was the final diagnosis for 19% of surgically-treated nodules...
July 2017: Journal of Zhejiang University. Science. B
https://www.readbyqxmd.com/read/28680105/braf-and-nras-mutations-in-papillary-thyroid-carcinoma-and-concordance-in-braf-mutations-between-primary-and-corresponding-lymph-node-metastases
#16
Najla Fakhruddin, Mark Jabbour, Michael Novy, Hani Tamim, Hisham Bahmad, Fadi Farhat, Ghazi Zaatari, Tarek Aridi, Gernot Kriegshauser, Christian Oberkanins, Rami Mahfouz
Concordance between mutations in the primary papillary thyroid carcinoma (PTC) and the paired x lymph node metastasis may elucidate the potential role of molecular targeted therapy in advanced stages. BRAF and NRAS mutations in primary PTC (n = 253) with corresponding metastatic lymph node (n = 46) were analyzed utilizing StripAssays (ViennaLab Diagnostics). Statistical analysis was performed using (SPSS, Inc.), version 24.0 with a p-value of <0.05, and concordance via kappa agreement. BRAF mutation frequency in conventional PTC (cPTC): 56...
July 5, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28679352/identification-of-two-distinct-molecular-subtypes-by-digital-rna-counting-of-non-invasive-follicular-tumour-with-papillary-like-nuclear-features-niftp
#17
Riccardo Giannini, Clara Ugolini, Anello Marcello Poma, Maria Urpì, Cristina Niccoli, Rossella Elisei, Massimo Chiarugi, Paolo Vitti, Paolo Miccoli, Fulvio Basolo
Backgound. The follicular variant (FV) is one of the most common variants of papillary thyroid carcinoma (PTC). Clinically, the FVPTC is considered a low-risk variant of PTC, and the encapsulated forms of FVPTC represent a group of thyroid tumours with an overall good prognosis. Consequently, these neoplasms were very recently reclassified as "non-invasive follicular tumour with papillary-like nuclear features (NIFTP)". From a molecular standpoint, NIFTP appears similar to the follicular pattern thyroid neoplasm; however, limited data are currently available regarding their gene expression profile...
July 5, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28666074/prognostic-implication-of-braf-and-tert-promoter-mutation-combination-in-papillary-thyroid-carcinoma-a-meta-analysis
#18
REVIEW
Huy Gia Vuong, Ahmed M A Altibi, Uyen N P Duong, Lewis Hassell
INTRODUCTION: he use of molecular markers, especially BRAF and TERT promoter mutations, for risk stratification in papillary thyroid carcinoma (PTC) is subject to continuing debate. In this study, we aimed to investigate the clinicopathological implication of each genotype when combining BRAF and TERT promoter mutations in PTCs. METHODS: We searched four electronic databases including PubMed, Scopus, Web of Science and Virtual Health Library for relevant studies...
June 30, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/28659720/the-genetics-of-papillary-microcarcinomas-of-the-thyroid-diagnostic-and-prognostic-implications
#19
REVIEW
Ana Cunha Rodrigues, Gustavo Penna, Elisabete Rodrigues, Patrícia Castro, Manuel Sobrinho-Simões, Paula Soares
Papillary microcarcinoma of the thyroid (mPTC) is defined by the WHO as a papillary thy-roid cancer measuring 10mm or less in diameter and it is nowadays a topic of intense debate among the members of the medical community due to its apparent "epidemic" rise. Although these tumors follow almost always an indolent clinical course and carry an excellent prognosis, it is known that a small sub-set may display a potentially aggressive behavior. Nevertheless, we still lack an accurate way of predict-ing those which will cause significant disease...
June 2017: Current Genomics
https://www.readbyqxmd.com/read/28656062/c-myc-is-required-for-braf-v600e-induced-epigenetic-silencing-by-h3k27me3-in-tumorigenesis
#20
Yiping Qu, Qi Yang, Juan Liu, Bingyin Shi, Meiju Ji, Gang Li, Peng Hou
BRAF(V600E) mutation is frequently found in human cancers particularly thyroid cancer and melanoma, and is involved in the regulation of gene expression through activating MAPK/Erk signaling. Trimethylation of histone 3 lysine 27 (H3K27me3) is a critical epigenetic mark for the maintenance of gene silencing in tumorigenesis. However, molecular mechanism underlying the complex interplay between these two molecular events remains to be explored. In the present study, we conducted chromatin immunoprecipitation combined with next-generation sequencing (ChIP-Seq) and expression microarray analysis in NIH3T3 cells to explore the relationship between H3K27me3 and transcriptional regulation by BRAF(V600E) mutation...
2017: Theranostics
keyword
keyword
17698
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"